Patients
| Country | Value | Year |
|---|---|---|
| Iraq | 39.7 | 2024 |
| Jordan | 35.4 | 2024 |
| Lebanon | 30.7 | 2024 |
| Palestine | 37.4 | 2024 |
| Qatar | 42.0 | 2024 |
| Saudi Arabia | 40.1 | 2024 |
| Syria | 33.0 | 2024 |
| UAE | 31.6 | 2024 |
| Yemen | 13.3 | 2024 |
Updated
Reviewed by Chandani Patel
Middle East GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.56 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.94 Bn | — | — |
| 2025 (base) | $2.30 Bn | +$364.6 Mn | — |
| 2026 (forecast) | $2.74 Bn | +$433.1 Mn | +18.8% |
| 2027 (forecast) | $3.25 Bn | +$514.6 Mn | +41.1% |
| 2028 (forecast) | $3.86 Bn | +$611.3 Mn | +67.7% |
| 2029 (forecast) | $4.59 Bn | +$726.2 Mn | +99.2% |
| 2030 (forecast) | $5.45 Bn | +$862.7 Mn | +136.6% |
| 2031 (forecast) | $6.48 Bn | +$1.02 Bn | +181.1% |
| 2032 (forecast) | $7.69 Bn | +$1.22 Bn | +234% |
| 2033 (forecast) | $9.14 Bn | +$1.45 Bn | +296.8% |
| 2034 (forecast) | $10.86 Bn | +$1.72 Bn | +371.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.30 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $10.86 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, route of administration, application and end user (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.
Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.
The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in GLP-1 Receptor Agonists right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Iraq | 39.7 | 2024 |
| Jordan | 35.4 | 2024 |
| Lebanon | 30.7 | 2024 |
| Palestine | 37.4 | 2024 |
| Qatar | 42.0 | 2024 |
| Saudi Arabia | 40.1 | 2024 |
| Syria | 33.0 | 2024 |
| UAE | 31.6 | 2024 |
| Yemen | 13.3 | 2024 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 3 shared keywords
Middle East · 3 shared keywords
Middle East · 2 shared keywords
Middle East · 2 shared keywords
Middle East · 2 shared keywords
Middle East · 2 shared keywords
Public Health · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Public Health · Middle East